Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Francesca Bruce
Canada plans to run regulatory reviews and health technology appraisals in parallel for certain new medicines. This could mean some companies get their drugs listed on public health plans almost immediately upon market authorization, rather than having to wait for more than a year.
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.
Health authorities in Ontario, Canada, have become the first to offer a universal drug program offering younger patients access to free medicines. The move could be a small step towards eventually establishing a National Pharmacare Program across Canada.
An agreement between Brazil’s medicines regulator, ANVISA, and the National Institute of Industrial Property, INPI, aimed at clearly defining their respective roles in the patent application process could pose a threat to the patent system, say IPR experts.
Companies could find Brazil a more attractive place to conduct clinical trials thanks advances in digital healthcare and a new law that will cut bureaucracy and shorten approval timelines for trials.
Newly passed UK legislation gives the government powers to curb pricing of unbranded generics when market forces fail. The Association of the British Pharmaceutical Industry has welcomed amendments to draft legislation that have addressed its concerns over onerous requirements.